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Abstract
Background: Biliary papillomatosis (BP) is a rare disease entity with a strong malignant potential.
It is characterized by multiple papillary adenomas involving both the intrahepatic and extrahepatic
biliary tree. BP was considered in the past to be a disease with low malignant potential. However,
a current review of the English literature revealed a high rate of malignant occurrence of
approximately 41% and histological analysis along with the expression pattern of mucin core
proteins (MUC) and mucin carbohydrate antigens suggests that BP is a borderline or low grade
malignant neoplasm with a high malignant potential.
Case presentation: A 68 year-old male patient was referred to our hospital due to the presence
of sudden right upper quadrant abdominal pain, nausea and dark urine. Imaging workup
demonstrated dilatation of the left hepatic duct without the presence of a space-occupying lesion.
A left hepatectomy and cholecystectomy were carried out and histological analysis revealed a
moderately to poorly differentiated carcinoma of the left hepatic duct in the background of biliary
papillomatosis. Postoperative course was uneventful. Unfortunately, two years after initial diagnosis
the patient rapidly deteriorated and died from multiple pulmonary secondary deposits.
Conclusion: BP should not be considered to be a benign disease. The clinical behavior, the high
recurrence rate and the even higher malignant transformation occurrence, as well as the presence
of carcinogenetic indicators (K-ras mutation, overexpression of p53, MUC and Tn antigens)
strongly support that BP is a low-grade neoplasm with high malignant potential.
Background
Biliary papillomatosis (BP) is defined as papillary prolif-
eration of the lining epithelium of the bile duct tree, fur-
ther classified into 5 classes according to the degree of
cytological and structural atypia (increased nuclear/cyto-
plasmic ratio, loss of polarity, hyperchromatism, pleo-
morphism, prominent nucleoli, abnormal mitosis,
cribriform pattern and multilayering, and presence of
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invasion); thus, class 1 is defined as BP with low-grade
atypia, class 2 as BP with high-grade atypia, class 3 as BP
with in situ carcinoma, class 4 as BP with microscopic foci
of stromal invasion and class 5 as BP with definite inva-
sion into the hepatic parenchyma or fibromuscular layer
of the bile duct wall [1]. In the present study a case of a
class 5 BP involving the left hepatic duct is reported. A dis-
cussion of clinico-pathologic characteristics, diagnostic
modalities and therapeutic management of the disease as
well as a review of the English literature is presented.
Case presentation
A 68 year-old male patient was referred to our surgical
department from another hospital's medical department
with a presenting clinical picture of sudden right upper
quadrant abdominal pain, nausea and dark urine. With
an initial diagnosis of obstructive jaundice possibly due to
choledocholithiasis the patient was admitted to our
department for further investigation. The patient's past
medical history included upper gastrointestinal bleeding
and chronic pulmonary obstructive disease.
Tumor markers (CEA, CA19-9, a-FP) were normal, while
a mild elevation of the cholestatic enzymes (ALP = 138
IU/L, γ-GT = 95 IU/L) were demonstrated with return to
normal of bilirubin and transaminases.
Abdominal ultrasound, computed tomography and mag-
netic resonance imaging (Fig. 1) demonstrated dilatation
of the left intrahepatic bile ducts without the presence of
any space-occupying lesion. Triplex ultrasonography of
the liver confirmed the patency of portal and hepatic veins
and of the hepatic artery.
Endoscopic retrograde and magnetic resonance cholan-
gio-pancreatographies showed anomalous dilatation of
the left intrahepatic bile ducts with a concomitant milder
dilatation of the pancreatic duct, as well as mucus dis-
charge from the papilla of Vater during endoscopy.
Colonoscopy was performed to rule out primary bowel
neoplasm and revealed the presence of large bowel pol-
yps. Snare polypectomies were performed and the histo-
logical analysis demonstrated the presence of tubulous
and tubulovillous adenomas of the colon with mild to
moderate degree of epithelial dysplasia.
Total bone scan with Tc99 m MDP, thoracic computed
tomography and brain magnetic resonance imaging were
negative for secondary deposits.
With a diagnosis of a cholangiocarcinoma a left hepatec-
tomy with inflow occlusion (Pringle's maneuver) and
selective hepatic vascular exclusion and cholecystectomy
were carried out. The histology report describes the pres-
ence of foci of papillary adenomas with a fibrovascular
core connecting each of them with the ductal wall, the
cuboidal or columnar cells lining the bile duct epithelium
and the presence of excessive intraductal mucus, as well as
foci of a moderately to poorly differentiated carcinoma,
with sporadic necrotic areas and invasion of the fibrously
thickened intrahepatic bile ducts (Fig 2, 3).
The postoperative course was uneventful and the patient
was discharged on the 9th postoperative day. Despite an
uncomplicated 2 year follow-up period, the patient rap-
idly deteriorated and died from multiple pulmonary met-
astatic deposits.
Discussion
Since the first case of biliary papillomatosis reported by
Chappet in 1894 [2] approximately 140 cases have been
published in the literature [1,3-5]. BP is characterized by
numerous papillary tumors of variable distribution in the
intrahepatic and/or extrahepatic biliary tree, extending
superficially along the bile duct mucosa [1]. The course of
the disease is complicated by the occurrence of malignant
transformation and the consequences of chronic cholesta-
sis due to mechanical obstruction from large amounts of
mucus [5], an enlarging papilloma or tumor emboli [4],
resulting in septic cholangiitis and, finally, hepatic failure
[3].
Biliary papillomatosis is an unusual disease entity com-
monly affecting adults older than 60 years-old [4], with a
male:female ratio of 2:1 [6]. In one of the greatest series
reported ever, Lee et al [1] classifies BP as mucin-hyperse-
creting (MBP) and non-producing (NMBP), according to
the presence of mucobilia which is commonly found dur-
ing endoscopy. However, no differences were found in
survival rates among the two groups.
The clinical picture of BP consists of recurrent colicky
abdominal pain, repeated episodes of acute cholangitis
with fever and jaundice, due to partial or intermittent
obstruction of the bile duct by mucus, enlarging adeno-
mas or tumor fragmentations [1,5-7]. The disease involves
the extrahepatic ducts alone in 58% of cases, both extra-
and intra-hepatic ducts in 33% and intrahepatic ducts
alone in 9% [8].
Several pathogenetic mechanisms have been proposed,
but a definite one remains to be elucidated. Recurrent
pyogenic cholangitis, congenital choledochal cysts and
chronic stimulation from lithiasis, infection or pancreatic
juice are some of the mechanisms reported to be associ-
ated with the papillary appearance of the bile duct epithe-
lium [4].World Journal of Surgical Oncology 2006, 4:71 http://www.wjso.com/content/4/1/71
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An enlarged intrahepatic and/or common bile duct with
concomitant ill-defined filling defects consist the primary
imaging features of BP. Ultrasound can demonstrate non-
specific bile duct dilatation and intraductal solid masses
with no distal acoustic shadowing. Endoscopic and mag-
netic resonance cholangiopancreatograms usually show
multiple irregular filling defects. In ERCP, direct visualiza-
tion of excessive mucus discharge from the papilla of
Vater, as well as lack of motility on irrigation are typical
endoscopic features, while the presence of intraductal
masses connecting with a pedicle to the bile duct wall
demonstrated in MRCP consist the key radiological fea-
tures of BP [7,8]. However, diagnosis is frequently delayed
due to the resemblance of the clinical picture and radio-
logical findings to bile duct stones. Therefore, a past med-
ical history with recurrent episodes of cholangitis and the
lack of stone retrieval during ERCP should be considered
as highly suspicious in differentially diagnosing BP [4].
Lai et al [9] report that the use of endoscopic ultrasonog-
raphy (EUS) significantly underestimated the extent of the
intrahepatic disease, emphasizing the utility of direct vis-
ualization of the biliary tree by means of choledochos-
copy.
Tsui et al [10] have defined the characteristic cytologic fea-
tures of BP on fine needle aspiration (FNA): a combina-
tion of hypercellular smear, very broad and often double
cell layered sheets of ductal columnar epithelium, papil-
lary configuration, preserved honeycomb pattern with
Abdominal magnetic resonance imaging demonstrating the dilated left hepatic duct, without the presence of any space-occupy- ing lesion Figure 1
Abdominal magnetic resonance imaging demonstrating the dilated left hepatic duct, without the presence of any space-occupy-
ing lesion.World Journal of Surgical Oncology 2006, 4:71 http://www.wjso.com/content/4/1/71
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even nuclear spacing and dysplastic but not frankly malig-
nant nuclear features.
Biliary papillomatosis was considered in the past to be a
disease with low malignant potential. However, a current
review of the English literature revealed a high rate of
malignant occurrence of approximately 41% [4]. Addi-
tionally, Lee et al [1] reports that in 83% of 58 patients
with BP a coexisting carcinoma was diagnosed after taking
biopsies from adenomas cholangioscopically or examin-
ing histologically the surgical specimens. Additionally,
Amaya et al [11] report that histological analysis along
with the expression pattern of mucin core proteins (MUC)
and mucin carbohydrate antigens suggests that BP is a
borderline or low grade malignant neoplasm. Further-
more, point mutations of K-ras oncogene and overexpres-
sion of p53 have been described in BP arising in a
congenital choledochal cyst, without histological evi-
dence of malignancy [12]. Furthermore, Yamashita et al
[13] accomplished an immunohistological analysis in
patients with hepatolithiasis and intrahepatic bile-duct
carcinoma and suggest that the different expression and
production of mucin carbohydrates [Tn, sialosyl-Tn(STn),
and T antigens] and core proteins [MUC1-apomucin-
related antigen (ARA) and MUC2-ARA] by bile-duct cysta-
denocarcinomas and cholangiocarcinomas are markers of
a differing prognosis. Sasaki et al [14] report that intrahe-
patic cholangiocarcinomas extensively expressed MUC1
apomucin and focally expressed MUC2 apomucin. In
addition, cholangiocarcinoma of the hilar type frequently
expressed MUC3 apomucin, while MUC5/6 apomucin
was more frequently expressed in well-differentiated
tumors. More specifically, Shimonishi et al [15] report
that epithelial hypersecretion of sialomucin rather than
sulfomucin is prevalent in intraductal papillary neoplasia
of the liver (IPN-L), as well is the expression of cytokeratin
Histological section of an intrahepatic cholangiocarcinoma, papillary type (H&E stain, ×25) Figure 2
Histological section of an intrahepatic cholangiocarcinoma, papillary type (H&E stain, ×25).World Journal of Surgical Oncology 2006, 4:71 http://www.wjso.com/content/4/1/71
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(CK) 20, MUC2 and nuclear p53 immunostaining.
Higashi et al [16] suggest that MUC1 expression from
invasive cholangiocarcinomas is associated with poor
patient outcome, in contrary to expression of non-sia-
lylated MUC2 mucin which is thought to be a favourable
prognostic indicator.
Resection is the treatment of choice when BP is localized
according to preoperative imaging workup and with the
support of intraoperative ultrasound or cholangioscopy
[4,17-19]. If the patient cannot withstand or is not willing
to undergo major surgery, local ablation, stenting or
drainage palliative procedures are considered [4]. In the
case of diffuse BP liver transplantation is the treatment of
choice [20,21]. The multicentricity and diffuse pattern of
BP explains the high recurrence rate after surgical resec-
tion of the underlying lesion. Thus, bilobar or recurrent
disease, as well as the high risk of malignant transforma-
tion should favor total hepatectomy and liver transplanta-
tion to be considered as the ultimate curative approach.
Lee et al [3] report that after curative resection the 5-year
survival rate is 81%, while in patients undergoing pallia-
tive drainage the mean survival is 37 months, significantly
longer than that of cholangiocarcinoma.
Conclusion
BP should not be considered to be a benign disease. The
clinical behavior, the high recurrence rate and the even
higher malignant transformation occurrence, as well as
the presence of carcinogenetic indicators (K-ras mutation,
overexpression of p53, MUC and Tn antigens) strongly
support that BP is a low-grade neoplasm with high malig-
nant potential. Radical surgery and liver transplantation
Histological section of an intraductal papillary cholangiocarcinoma showing infiltrating carcinoma of the surrounding fibrous tis- sue (arrow) (H&E stain, ×25) Figure 3
Histological section of an intraductal papillary cholangiocarcinoma showing infiltrating carcinoma of the surrounding fibrous tis-
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should be considered as the only curative treatment
options in order to prolong survival.
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